The CEO of Anagenex believes that the company's AI engine trained on billions of data points and iterative testing will blow other AI drug discovery startups out of the water.
In this free webinar on June 9th at 11am ET, industry experts from Syneos and Medable will share their perspectives on how to address these drug development challenges within cardiometabolic clinical studies and provide input on the impact of new regulatory guidance such as the DEPICT Act. This engaging panel will discuss leveraging technology and home health solutions to augment existing points of care between patients and their clinical care team to improve the patient experience, drive more scientific rigor to data generation and achieve timely endpoint capture.
Not able to attend?We recommend you still register and you will receive an email with how to access the recording of the event.
Don't miss out on this valuable opportunity to meet and discuss the latest trends and opportunities. Don't miss your chance to save with the Super Early Bird Rate.
By Arundhati Parmar Wednesday, June 8, 2022 8:00 AM
The CEO of Anagenex believes that the company's AI engine trained on billions of data points and iterative testing will blow other AI drug discovery startups out of the water.
PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue Phase 1 study with the goal of advancing to Phase 2 early next year.
Health systems are seeing increased operational efficiency after applying machine learning analytics to their operating room block scheduling. Given the multitude of challenges health systems face — from increased labor costs to material shortages to reimbursement woes — some health system digital executives say it's critical that hospitals incorporate machine learning into their block schedules sooner rather than later.
AWS may be emerging as the healthcare sector's cloud darling, as healthcare customers are reporting high levels of satisfaction and large health systems are beginning to ink long-term cloud partnership plans. Healthcare organizations that choose AWS over its competitors do so because they believe it's the most mature and healthcare-focused cloud platform, according to a KLAS report released Tuesday.
Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.
A 20-year veteran in the legal operations field and co-founder of Corporate Legal Operations Consortium (CLOC) discusses how she sees the future of the industry and why to only use law firms when you really need them.
RPM as we know it today – with all its advantages – falls short. The reason? Monitoring and alerting alone cannot provide one of the most critical parts of healthcare: care itself.
No comments